JP2017514850A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514850A5
JP2017514850A5 JP2016566238A JP2016566238A JP2017514850A5 JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5 JP 2016566238 A JP2016566238 A JP 2016566238A JP 2016566238 A JP2016566238 A JP 2016566238A JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
htbz
isoquinolin
hours
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514850A (ja
JP6635945B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029519 external-priority patent/WO2015171802A1/en
Publication of JP2017514850A publication Critical patent/JP2017514850A/ja
Publication of JP2017514850A5 publication Critical patent/JP2017514850A5/ja
Application granted granted Critical
Publication of JP6635945B2 publication Critical patent/JP6635945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566238A 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター Active JP6635945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181949A Division JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Publications (3)

Publication Number Publication Date
JP2017514850A JP2017514850A (ja) 2017-06-08
JP2017514850A5 true JP2017514850A5 (https=) 2018-06-14
JP6635945B2 JP6635945B2 (ja) 2020-01-29

Family

ID=53264772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016566238A Active JP6635945B2 (ja) 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Country Status (24)

Country Link
US (3) US20170071932A1 (https=)
EP (3) EP3139925B1 (https=)
JP (4) JP6635945B2 (https=)
KR (5) KR20200133003A (https=)
CN (3) CN106456629A (https=)
AU (1) AU2015256012B2 (https=)
CA (1) CA2947736C (https=)
CY (1) CY1125058T1 (https=)
DK (2) DK3936130T3 (https=)
ES (2) ES2976207T3 (https=)
FI (1) FI3936130T3 (https=)
HR (2) HRP20240459T1 (https=)
HU (2) HUE057839T2 (https=)
IL (1) IL248745B (https=)
LT (2) LT3936130T (https=)
MX (1) MX387625B (https=)
NZ (1) NZ725826A (https=)
PL (2) PL3936130T3 (https=)
PT (2) PT3139925T (https=)
RS (2) RS65359B1 (https=)
RU (1) RU2753740C2 (https=)
SI (2) SI3139925T1 (https=)
SM (2) SMT202400199T1 (https=)
WO (1) WO2015171802A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193767A (en) * 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
EP3568394A1 (en) 2017-01-10 2019-11-20 Sandoz AG Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
CN110678181A (zh) * 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CA3081709A1 (en) 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
EP3784237B1 (en) * 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MA55893A (fr) * 2019-05-09 2022-03-16 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) * 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Similar Documents

Publication Publication Date Title
JP2017514850A5 (https=)
AU2018256605C1 (en) Benzoquinone Derivative E3330 in Combination with Chemotherapeutic Agents for the Treatment of Cancer and Angiogenesis
JP6635945B2 (ja) 多動性運動障害を処置するためのｖｍａｔ２インヒビター
PH12020550238A1 (en) Methods for the administration of certain vmat2 inhibitors
JP7221922B2 (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
JP2017525718A5 (https=)
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
BR112014003061A2 (pt) composição farmacêutica com sabor mascarado
JP2016540738A5 (https=)
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
RU2014102362A (ru) Антитромботические соединения
JP2015038155A5 (https=)
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2013508289A5 (https=)
JP2017513809A5 (https=)
PH12022550790A1 (en) Oral complement factor d inhibitors
JP2015509539A5 (https=)
MX2026001199A (es) Inhibidores del factor d del complemento para administracion oral
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
JP2016515550A5 (https=)
JP2015504094A5 (https=)
JP2016512247A5 (https=)
RU2019109695A (ru) Лекарственная форма для пролонгированного ослабления симптомов
JP2019516726A5 (https=)
RU2018104691A (ru) Композиции с модифицированным высвобождением ницерголина